Cordovacann Financials

LVRLF

Source SEC Filings (10-K/10-Q) Updated Jun 30, 2021 Currency USD FYE June

This page shows Cordovacann (LVRLF) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. All figures are derived from SEC filings (10-K and 10-Q reports).

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$2.6M

Cordovacann reported -$2.6M in net income in fiscal year 2021.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

N/A

Cash & Debt

$1.1M

Cordovacann held $1.1M in cash against $0 in long-term debt as of fiscal year 2021.

Dividends Per Share

N/A

Shares Outstanding

93M

Cordovacann had 93M shares outstanding in fiscal year 2021.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

N/A

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

N/A

LVRLF Income Statement

Metric	FY21
Revenue	N/A
Cost of Revenue	N/A
Gross Profit	N/A
R&D Expenses	N/A
SG&A Expenses	N/A
Operating Income	N/A
Interest Expense	N/A
Income Tax	$315K
Net Income	-$2.6M
EPS (Diluted)	N/A

LVRLF Balance Sheet

Metric	FY21
Total Assets	N/A
Current Assets	N/A
Cash & Equivalents	$1.1M
Inventory	N/A
Accounts Receivable	N/A
Goodwill	N/A
Total Liabilities	N/A
Current Liabilities	N/A
Long-Term Debt	N/A
Total Equity	N/A
Retained Earnings	N/A